jump to content jump to footer

Early Detection of Treatment Response in Lung Cancer Using Delta-Radiomics Features

The study conducted by Heidelberg University Hospital investigates the use of diffusion-weighted MRI (DWI) to predict early treatment outcomes in patients with advanced lung adenocarcinoma. The researchers analyzed changes in radiomic features derived from ADC (Apparent Diffusion Coefficient) maps in 144 patients who were treated with either tyrosine kinase inhibitors (TKI) or platinum-based chemotherapy (PBC).

The study found that radiomic features, known as delta-radiomics features (DRFs), were able to predict treatment success and progression-free survival (PFS) as early as 14 days after the start of treatment.

These features enabled the distinction between patients with likely better and worse treatment outcomes.

The use of DWI-based radiomics shows promising potential for early decision-making in lung cancer treatment and could allow physicians to adjust therapies more quickly.

This approach offers a non-invasive, radiation-free alternative for early assessment of treatment success in lung cancer.

Read more about the study here.

Research with mint mintLesion Clinical Research MRI Personalized Therapy Therapy Response Assessment Radiomics Texture Analysis

Related Resources

Participants at the RECIST and Beyond workshop in Cologne during hands-on training with mint Lesion for structured tumor response assessment.
The two-day “RECIST and Beyond” workshop at radCIO Cologne offered intensive hands-on training on RECIST, iRECIST, mRECIST and LI-RADS, with real-case reporting performed directly in mint Lesion.
Successful “RECIST and Beyond” Workshop in Cologne: Advancing Precision in Oncologic Imaging
How can complex tumor findings be assessed accurately, reproducibly, and in line with clinical guidelines?
Screenshot of the mint Lesion interface showing RANO 2.0 configuration, tumor burden calculations, and structured neuro-oncology assessment tools.
mint Lesion fully supports RANO 2.0 implementation with configurable parameters, automated tumor burden calculations, and structured workflows for neuro-oncology clinical trials.
Implementing RANO 2.0 for Neuro-Oncology Clinical Trials in mint Lesion
Tumor response assessment in neuro-oncology clinical trials requires careful attention to measurement protocols and confirmation scan requirements. To…
Image of a patient getting an MRI scan, signifying how RACOON projects in Germany show how imaging, structured reporting, and AI jointly advance clinical research.
Overview of major RACOON projects in radiology and clinical research.
RACOON – Imaging, Data & Collaboration for Better Decisions
Modern radiology faces a central question: how can imaging and clinical data be combined in a way that leads to more precise diagnoses,…